Finerenone is a novel third-generation nonsteroidal mineralocorticoid receptor antagonist (MRA) that has demonstrated efficacy in treating chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF). The gene discussed is NR3C2; the disease is heart failure.